AVE 20.0% 0.3¢ avecho biotechnology limited

prophase financials, page-42

  1. 563 Posts.
    lightbulb Created with Sketch. 1
    It does look quite an optimistic throw, given:-
    - the cost of thoese launches, not just upfront but sustained for a period
    - POH's quite remarkable lack of human & financial resources in this context
    - a product's inherent qualities are only a minor part of the equation, particularly in cosmetics.
    - From what has benn reported on the Elixia trial, it was a desperately amateur effort; no doubt they leant a lot, but it does seem to highlight a lack of expertise.


    A good summary of the risks. Given you have some experience in this arena dougal, could you take a stab at how much in $ terms you think is needed for a global launch? Just trying to get a breakdown of how the recent capital will be deployed.

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.001(20.0%)
Mkt cap ! $9.507M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $408 154.2K

Buyers (Bids)

No. Vol. Price($)
61 90794613 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 54998583 13
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.